Cytokinetics Inc (NASDAQ: CYTK) stock enjoyed a major increase of 15.3% on 1/8/24. The shares closed at $108.06. Moreover, this advance was accompanied by exceptionally high trading volume at 501% of normal. The stock has risen 29.8% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
CYTK's future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to be a major Value Eraser.
Cytokinetics is currently unrated.
Rating Review
The stock is currently unrated.